Swayampakula Ramakanth

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency. Adrenocortical...

Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according to H.C. Wainwright. The Analyst Analyst Swayampakula Ramakanth initiated coverage of...

Cesca Therapeutics Inc (NASDAQ: KOOL) is poised to make much headway with its automated CAR-T manufacturing platform CAR-TXpress, according to H.C. Wainwright.  CAR-T-cell therapy is a method of treating cancer by using a patient's immune system cells —  T cells —...

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments. The stock could see significant upside if later-stage bladder cancer trials set for mid-2018 prove to...

If investors were to sum up the year 2017 for specialty drug maker RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) in one phrase, it might be this: “catalyst-rich.” A specialty biopharmaceutical company based in Israel, RedHill has a treasure trove of developing drugs in its pipeline to...

Biopharmx Corp (NYSE: BPMX) shares have moved 38 percent higher in 2017 as the company progresses its dermatology-centric drugs through the pipeline. The Silicon Valley-based pharmaceutical currently has its lead candidate, BPX-01, undergoing both a Phase 2b dose finding trial for the treatment of...

HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...

H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd (NASDAQ: VBLT), it could revolutionize the multi-billion dollar angiogenesis inhibitor market. Ramakanth initiated coverage of the company with a Buy rating...

H.C. Wainwright’s Swayampakula Ramakanth mentioned that CARDIOME PHARMA CORP (NASDAQ: CRME) “has an experienced in-hospital sales force and is developing a niche business model in the fragmented and difficult-to-operate $100B European hospital pharmacy market.” Ramakanth...

In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth initiated coverage of Novogen Limited (ADR) (NASDAQ: NVGN) with a Buy rating and $8.50 price target. The company has three drug candidates that target an addressable market worth $38 billion and are expected to be...